NEW YORK (GenomeWeb News) – New Zealand cancer diagnostics company Pacific Edge said today its US Laboratory has achieved registration under the CLIA regulatory process, setting the stage for it to offer its bladder cancer test in the US.

CLIA registration means that Pacific Edge's laboratory in Hershey, Penn., will be able to operate and process urine samples from patients in the US for its laboratory-developed test called Cxbladder. The non-invasive, urine-based test uses molecular signatures to identify the presence of bladder cancer tumors.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: omic analysis of permafrost microbes, hookworm genome, and more.

Biologists turn to environmental DNA sampling to determine whether elusive or invasive species are shedding DNA in a given area.

Rob Knight writes at Scientific American that microbiome studies are about to break out of the laboratory.

Harold Varmus, the director of the National Cancer Institute, has announced that he is stepping down after nearly five years.